This year’s Eric D. Hadar Distinguished Lecturer, Dr. Rajita Sinha, will present “Can We Rescue Stress and Trauma Related Pathophysiology in Addiction to Improve Treatment Outcomes?” on Nov. 16, 2022.
In an accompanying editorial, Dr. Joshua T. Kantrowitz explained how the future role of lumateperone could be crucial in treating schizophrenia patients.
Dr. Michael Grunebaum says that in his clinical trials, many patients don’t find that the drug relieves anxiety. “Ketamine is just a really distinct, weird, spacey feeling,” he says.
A discussion with Dr. Deborah Cabaniss and Dr. Yael Holoshitz about their new book Different Patients, Different Therapies: Optimizing Treatment Using Differential Psychotherapuetics.
“The efficacy and safety profile of CAPLYTA approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia,” said Dr. Jeffrey A. Lieberman.
The study suggests that some of the ways schools cope with student suicides might prove useful in the aftermath of a school shooting, Dr. Mark Olfson said.
Dr. Elias Dakwar said he became interested in ketamine as a potential treatment for alcohol use disorder after seeing good results from using the drug to treat cocaine addiction.
Researchers findings at Columbia University Vagelos College of Physicians and Surgeons and New York State Psychiatric Institute could lead to a new approach to the treatment of alcohol use disorder.
"The rate at which individuals relapsed and overdosed after ending treatment was alarmingly high, suggesting that discontinuing buprenorphine is a life-threatening event," said Dr. Williams.